# Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia

> **NCT00776321** · PHASE2 · COMPLETED · sponsor: **Karo Bio AB** · enrollment: 142 (actual)

## Conditions studied

- Primary Hypercholesterolemia

## Interventions

- **DRUG:** Eprotirome
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00776321
- **Lead sponsor:** Karo Bio AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2008-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00776321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00776321, "Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00776321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*